Cite this page
FeedbackGout is a type of inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in tissues and joints as a result of persistent hyperuricemia. The condition includes acute attacks of joint swelling and pain, followed by periods of remission. Progression to chronic gout may be accompanied by accumulation of MSU crystals, also called tophi, in joints or other soft tissue. Accurate gout diagnosis is important to ensure proper treatment and medical management; it is particularly important to differentiate gout from conditions such as rheumatoid arthritis and septic arthritis because treatment of these conditions differs. Detection of MSU crystals in synovial fluid aspirate remains the standard for definitive diagnosis; however, this technique is painful and often technically difficult. The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) have developed a scoring system based on clinical and laboratory findings to aid in the diagnosis of gout.
Quick Answers for Clinicians
Hyperuricemia is a common condition and is classified by elevated serum urate concentrations. The most common complication of hyperuricemia is gout. However, many cases of hyperuricemia are asymptomatic. In patients with gout, serum urate concentrations are generally high, but can be normal at the time of an acute gout flare. The presence of hyperuricemia aids in the clinical diagnosis of gout, but it does not definitively confirm the diagnosis. Persistently low serum urate concentrations make the diagnosis of gout less likely. The Criteria for Diagnosis section has more detailed information about the definitive diagnosis of gout.
Imaging methods such as radiography and magnetic resonance imaging (MRI) may be useful in monitoring the progression of joint erosion or tophus size in chronic gout. Ultrasound and dual-energy computed tomography (DECT) are used to detect urate deposition in symptomatic joints. All of these imaging modalities are included in the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) gout classification criteria. Imaging alone is insufficient to definitively diagnose gout and should be used in addition to laboratory testing methods.
Gout is caused by deposition of monosodium urate (MSU) crystals in tissues and joints, whereas pseudogout is caused by calcium pyrophosphate crystal deposition. For this reason, pseudogout is formally called calcium pyrophosphate crystal deposition (CPPD) disease. The diagnosis of CPPD also involves synovial fluid and crystal analysis.
Indications for Testing
Laboratory testing for gout may be appropriate in people who have experienced at least one episode of peripheral joint or bursal swelling, pain, or tenderness. Definitive diagnosis of suspected gout is important to ensure proper treatment.
Criteria for Diagnosis
The ACR/EULAR gout classification criteria were developed to provide guidance for the diagnosis of gout. The entry criterion requires the occurrence of at least one episode of peripheral joint or bursal swelling, pain, or tenderness. If MSU crystals are present in the synovial fluid, a definitive diagnosis can be made. If the presence of MSU crystals cannot be confirmed, the scoring system below should be utilized. A threshold score of ≥8 is considered diagnostic for gout.
| Category | Criteria | Characteristic | Score |
|---|---|---|---|
| Clinical | Pattern of joint/bursa involvement during symptomatic episode(s) (ever)b | Ankle or midfoot (as part of monoarticular or oligoarticular episode without involvement of the first metatarsophalangeal joint) | 1 |
| Involvement of the first metatarsophalangeal joint (as part of monoarticular or oligoarticular episode) | 2 | ||
| Characteristics of symptomatic episode(s) (ever) |
Erythema overlying affected joint (patient reported or physician observed) Inability to bear touch or pressure to affected joint Great difficulty with walking or inability to use affected joint |
1 characteristic | 1 |
| 2 characteristics | 2 | ||
| 3 characteristics | 3 | ||
| Time course of symptomatic episode(s) (ever) |
Symptomatic episode is defined as an event with the presence of ≥2 of the following criteria, irrespective of anti-inflammatory treatment:
|
1 typical episode | 1 |
| Recurrent typical episodes | 2 | ||
| Tophus | Clinical evidence of tophus | Present | 4 |
| Laboratory | Serum urate | <4 mg/dL (<0.24 mmol/L) | -4 |
| 4-<6 mg/dL (0.24-<0.36 mmol/L) | 0 | ||
| 6-<8 mg/dL (0.36-<0.48 mmol/L) | 2 | ||
| 8-<10 mg/dL (0.48-<0.60 mmol/L) | 3 | ||
| ≥10 mg/dL (≥0.60 mmol/L) | 2 | ||
| Synovial fluid analysis of a symptomatic (ever) joint or bursa for MSU crystals | MSU crystal negative | -2 | |
| Imagingc | Imaging evidence of urate deposition in symptomatic (ever) joint or bursa | Present | 4 |
| Imaging evidence of gout-related joint damage | Present | 4 | |
|
aA web-based calculator can be accessed at https://goutclassificationcalculator.auckland.ac.nz, and through the ACR and EULAR websites. bSymptomatic episodes are periods that include any swelling, pain, and/or tenderness in a peripheral joint or bursa. cIf imaging is not available, score these items as 0. |
|||
Laboratory Testing
Diagnosis
Polarized Light Microscopy
The detection of MSU crystals in synovial fluid using polarizing microscopy is diagnostic of gout and the preferred approach for diagnosis. MSU crystals are needle shaped and negatively birefringent. Absence of these crystals does not necessarily eliminate the possibility of gout, but it makes gout less likely (as reflected by a negative value in the ACR/EULAR classification criteria scoring system). Although this method is preferred for diagnosis, it is not always feasible. Joint aspiration may be difficult in small joints, and polarized light microscopy is not available in all clinical settings. As such, MSU crystal detection is an unfeasible universal diagnostic standard, but this method of evaluation should be used when possible.
Serum Uric Acid
The serum urate concentration is considered a mandatory element of the classification criteria scoring system; in other words, the score cannot be calculated without it. In patients with gout, serum urate concentrations are generally elevated; however, serum urate levels are not always elevated at the time of an acute gout flare. Ideally, serum urate is measured >4 weeks after an acute attack. Treatment with urate-lowering therapy interferes with serum urate measurement.
Synovial Fluid Examination
Additional synovial fluid examination is sometimes required after MSU crystal analysis and is generally useful to differentiate between gout and septic arthritis. Helpful tests include absolute white blood cell (WBC) count, gram stain, and culture.
Monitoring
For patients receiving urate-lowering medication, serum urate concentrations should be monitored and maintained at <6 mg/dL (360 mmol/L), given that urate is generally soluble up to that level. A lower serum urate level (<5 mg/dL; 300 mmol/L) may facilitate faster dissolution of crystals in patients with severe gout (tophi, chronic arthropathy, frequent attacks) until crystal dissolution is total and gout has resolved. Serum urate concentrations of <3 mg/dL are not recommended for the long term because some studies suggest that uric acid might protect against various neurodegenerative diseases.
Additional Testing
HLA-B*5801 Genotyping
HLA-B*5801 genotyping may be indicated in certain patient populations before initiation of allopurinol therapy to identify patients who are at increased risk for developing severe cutaneous adverse reactions to allopurinol (allopurinol hypersensitivity reaction).
ARUP Lab Tests
Aids in diagnosis and monitoring of gout
Quantitative Spectrophotometry
Aids in differentiating gout from septic arthritis
Cell Count/Differential
Stain/Microscopy
Automated Cell Count/Differential
Stain/Culture/Identification
Use to identify patients with increased risk for allopurinol-induced severe cutaneous adverse reactions (SCARs) based on the presence of the HLA-B*58:01 allele
For additional test information, refer to the HLA-B*58:01 Genotyping, Allopurinol Hypersensitivity Test Fact Sheet
Polymerase Chain Reaction/Sequence Specific Oligonucleotide Probe Hybridization
Test Fact Sheet(s)
Medical Experts
Pearson
Young
References
-
27802479
Qaseem A, McLean RM, Starkey M, et al. Diagnosis of acute gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):52-57.
PubMed -
26359487
Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative [published correction appears in Ann Rheum Dis. 2016 Feb;75(2):473]. Ann Rheum Dis. 2015;74(10):1789-1798.
PubMed -
29083565
George C, Minter DA. Hyperuricemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
PubMed -
25581951
Bădulescu M, Macovei L, Rezuş E. Acute gout attack with normal serum uric acid levels. Rev Med Chir Soc Med Nat Iasi. 2014;118(4):942-945.
PubMed -
31536213
Fenando A, Widrich J. Gout (podagra). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
PubMed -
ACR-EULAR Gout Classification Criteria Calculator
American College of Rheumatology, European League Against Rheumatism. ACR-EULAR gout classification criteria calculator. [Accessed: Jun 2020]
Online -
27457514
Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42.
PubMed -
26094938
Saito Y, Stamp LK, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99(1):36-37.
PubMed
